Intellia Therapeutics, Inc. is a genome editing company dedicated to discovering and developing therapeutic solutions. Its in vivo pipeline features leading candidates such as NTLA-2001, currently undergoing Phase 1 clinical evaluation for transthyretin amyloidosis, and NTLA-2002, designed to address hereditary angioedema. The company also pursues a range of liver-targeted initiatives, addressing conditions including hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.